Spruce Biosciences, Inc. (SPRB) stock
SPRBNasdaqPharmaceutical PreparationsFiscal year ends December 31
$40.84+0.35 (+0.86%)
Close on Nov 18, 2026Market cap $117.38MP/E –Yield –
Spruce Biosciences net income
Net income is the profit left for shareholders after every expense, interest and tax.
Spruce Biosciences's net income for the twelve months ending Jun 30, 2026 was -$51.35M. For fiscal 2025 it was -$38.97M. The highest annual figure on record is -$13.09M in fiscal 2019.
Annual net income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$38.97M | – |
| FY2024 | Dec 31, 2024 | -$53.04M | – |
| FY2023 | Dec 31, 2023 | -$47.92M | – |
| FY2022 | Dec 31, 2022 | -$46.18M | – |
| FY2021 | Dec 31, 2021 | -$42.29M | – |
| FY2020 | Dec 31, 2020 | -$29.54M | – |
| FY2019 | Dec 31, 2019 | -$13.09M | – |
Quarterly net income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$16.23M | – |
| Q1 FY2026 | Mar 31, 2026 | -$12.27M | – |
| Q4 FY2025 | Dec 31, 2025 | -$14.65M | – |
| Q3 FY2025 | Sep 30, 2025 | -$8.21M | – |
| Q2 FY2025 | Jun 30, 2025 | -$2.07M | – |
| Q1 FY2025 | Mar 31, 2025 | -$14.04M | – |
| Q4 FY2024 | Dec 31, 2024 | -$23.56M | – |
| Q3 FY2024 | Sep 30, 2024 | -$8.67M | – |
| Q2 FY2024 | Jun 30, 2024 | -$9.18M | – |
| Q1 FY2024 | Mar 31, 2024 | -$11.63M | – |
| Q4 FY2023 | Dec 31, 2023 | -$9.95M | – |
| Q3 FY2023 | Sep 30, 2023 | -$12.35M | – |
| Q2 FY2023 | Jun 30, 2023 | -$12.82M | – |
| Q1 FY2023 | Mar 31, 2023 | -$12.79M | – |
| Q4 FY2022 | Dec 31, 2022 | -$11.14M | – |
| Q3 FY2022 | Sep 30, 2022 | -$11.40M | – |
| Q2 FY2022 | Jun 30, 2022 | -$11.87M | – |
| Q1 FY2022 | Mar 31, 2022 | -$11.76M | – |
| Q4 FY2021 | Dec 31, 2021 | -$9.18M | – |
| Q3 FY2021 | Sep 30, 2021 | -$11.45M | – |
| Q2 FY2021 | Jun 30, 2021 | -$11.77M | – |
| Q1 FY2021 | Mar 31, 2021 | -$9.89M | – |
| Q4 FY2020 | Dec 31, 2020 | -$8.34M | – |
| Q3 FY2020 | Sep 30, 2020 | -$9.59M | – |
| Q2 FY2020 | Jun 30, 2020 | -$6.45M | – |
| Q1 FY2020 | Mar 31, 2020 | -$5.17M | – |
| Q4 FY2019 | Dec 31, 2019 | -$3.18M | – |
| Q3 FY2019 | Sep 30, 2019 | -$2.55M | – |
| Q2 FY2019 | Jun 30, 2019 | -$3.24M | – |
| Q1 FY2019 | Mar 31, 2019 | -$4.12M | – |
See a number that looks wrong?